Historically: Taken orally, usually once daily at bedtime with a glass of water. Not for current use.

Dantron stimulates peristaltic contractions of the colon by directly irritating the intestinal mucosa. It also reduces water absorption and increases electrolyte secretion into the lumen of the large intestine, leading to an increase in intraluminal fluid and softer stools, facilitating bowel movement.

• •Known hypersensitivity to Dantron or anthraquinones.
• •Acute abdominal conditions (e.g., appendicitis, inflammatory bowel disease, severe abdominal pain).
• •Bowel obstruction.
• •Severe dehydration.
• •Pregnancy and lactation.
• •Carcinogenicity concerns.

Not applicable (drug withdrawn). Historically, stored at room temperature, protected from light and moisture.

Symptoms include severe abdominal cramps, diarrhea, and significant fluid and electrolyte disturbances (e.g., hypokalemia). Management is supportive, involving fluid and electrolyte replacement. No specific antidote.

Contraindicated during pregnancy and lactation due to potential genotoxicity and excretion into breast milk. Potential risk to the fetus and breast-fed infant.